BioSpace’s Post

GSK on Wednesday announced it is restructuring an existing collaboration agreement with German biotech CureVac, focusing on their investigational mRNA vaccines for influenza and COVID-19 while withdrawing from other infectious disease projects. Under the amended contract, GSK will pay CureVac €400 million—or approximately $430 million upfront—and has pledged up to $1.13 billion in development, regulatory and sales milestones, as well as tiered royalties in the high-single to low-teens range. In return, GSK will gain full global rights to develop and commercialize CureVac’s investigational mRNA vaccines for influenza and COVID-19, including combination formulations. The restructured deal comes as CureVac undergoes a sweeping strategic restructuring initiative, also announced on Wednesday, and which includes a 30% layoff. #biotech #biopharma #pharma #layoffs #COVID19 #Flu

Breaking News: Zuellig Pharma and Substipharm Biologics Join Forces to Expand Imojev Vaccine Access in Asia 🌐💉 In a groundbreaking collaboration, Zuellig Pharma and Substipharm Biologics have forged a strategic alliance to broaden access to the Imojev vaccine across Asia. This partnership marks a significant step in enhancing vaccine distribution and availability, especially in regions where it is critically needed. Imojev, renowned for its efficacy against Japanese Encephalitis, will now see an extended reach, thanks to the combined efforts of these industry leaders. The collaboration aims to address healthcare gaps, ensuring that more communities in Asia can benefit from the protection offered by the Imojev vaccine. This alliance underscores the shared commitment of Zuellig Pharma and Substipharm Biologics to advancing public health in the region. As the news unfolds, it's evident that this collaboration has the potential to make a lasting impact on vaccine accessibility and contribute significantly to disease prevention in Asia. #BiopharmaNews #VaccineAccess #HealthcareCollaboration

> Press Release 19 June: WACKER & CordenPharma are pleased to announce their joint consortium has officially entered the pandemic readiness state as of 1 June 2024. Following a successful expansion and qualification phase, the companies are now in stand-by phase for at least five years. In the event of a new pandemic, WACKER and CordenPharma have taken the necessary steps to produce 80 million vaccine doses a year within an extremely short time, with most of the production steps taking place in Germany, and every production step occurring within the European Union. As part of the consortium, CordenPharma is ready to manufacture custom and standard lipids in our Frankfurt (DE) and Chenôve (FR) sites, as well as provide aseptic fill & finish and packaging of the chosen mRNA-based vaccine at our Caponago (IT) facility. In its site in Halle (Germany), WACKER will produce plasmid DNA (pDNA), which is an essential starting material for the manufacture of mRNA. Dr. Michael Quirmbach, CEO of CordenPharma Group, commented: “Obtaining the official confirmation of pandemic readiness by the German government is a major milestone for CordenPharma. I am extremely proud of our teams across the CordenPharma sites involved in establishing and delivering our pandemic readiness plan on schedule. We are now ready, together with our partner WACKER, to manufacture end-to-end mRNA-based vaccines for the German government and other customers.” “We have expanded our Halle site into a Competence Center for mRNA production,” said WACKER CEO Dr. Christian Hartel. “WACKER has invested over 100 million Euros in this expansion and created over 100 highly qualified jobs. Our expertise in making mRNA and LNPs will contribute to the fight against future pandemics. Together with CordenPharma, we are proud to serve the German government in its pandemic preparedness plans.” Read the full press release here: https://lnkd.in/d6vBdaPK #CordenPharma #wacker #pandemic #mrna #pdna #lipids #injectables #fillfinish #pharmaceuticals #vaccine #germany

Thoughts on this? >> GSK surrenders HSV vaccine hopes after phase 2 fail, ceding race to Moderna, BioNTech >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #pharmaceutical #competitivemarketing #biotech

📢 More News in Pharma GSK has signed a licensing agreement worth up to €1.4bn with CureVac to develop mRNA vaccines for flu, Covid-19, and avian flu. The deal includes an initial €400mn payment and potential milestone payments of €1.05bn, plus royalties. This agreement will allow GSK to develop combination vaccines for flu and Covid-19, positioning them against competitors like Moderna, Pfizer, and BioNTech SE. CureVac, who are facing commercialisation challenges and a significant drop in shares, will benefit from this cash injection and shift focus to early-stage oncology vaccines, cutting 30% of its workforce to save €25mn annually (𝐢𝐟 𝐲𝐨𝐮 𝐚𝐫𝐞 𝐞𝐟𝐟𝐞𝐜𝐭𝐞𝐝 𝐛𝐲 𝐭𝐡𝐢𝐬 𝐆𝐄𝐓 𝐈𝐍 𝐓𝐎𝐔𝐂𝐇 𝐖𝐈𝐓𝐇 𝐌𝐄). GSK will fully control vaccine development, enhancing its capabilities against evolving flu and Covid-19 variants. GSK's Chief Scientific Officer, Tony Wood, expressed enthusiasm for the partnership's potential to set new standards in mRNA vaccines. CureVac CEO, Alexander Zehnder, MD, MBA, emphasised the strategic shift to ensure long-term success despite the difficult decision to reduce staff. #Pharma #mRNA #vaccines #biotech #innovation #healthcare #virology #covid

Well done Osivax! On September 10, KM Biologics announced that it had signed an option agreement with Osivax SAS of France to exercise an exclusive license for the development, manufacture, and sale of the company's universal influenza vaccine candidate group in Japan. Under this agreement, KM Biologics will pay a lump sum in addition to royalties upon the exercise of the option. Osivax is a French biotech company established in 2017. The universal influenza vaccine candidate group is based on the company's novel self-nanoparticle platform technology, and the lead program OVX836 is in phase 2 clinical trials. In addition to seasonal influenza viruses, it is expected to be effective against pandemic influenza viruses, which may suddenly change antigens and cause a global epidemic. Based on this license option agreement, KM Biologics will pay a lump sum to Osivax. In addition, if the option is exercised, KM Biologics will pay additional lump sums, milestone payments in the development stage, and royalties based on sales. The specific amounts have not been disclosed. https://lnkd.in/g6tkgEAQ #frenchpharma #globalvaccine #vaccine #flupandemic #frenchbiotech

#News: Sanofi announced a deal worth up to $1.4 billion with Novavax on Friday for its #COVID19vaccine, giving the Maryland-based biotech a much-needed boost to its struggling business. The French pharma is dropping $500 million upfront for #Novavax’s #COVID19 #vaccine, with the goals of co-commercializing its current formulation as well as developing a combination vaccine for #COVID and #flu. An additional $700 million is up for grabs in milestone payments. Along with another potential $200 million in milestones for additional vaccines made with Novavax’s Matrix #adjuvanttechnology, deal totals $1.4 billion—more than double the #biotech’s current market cap of $627 million. Read more from BioSpace 👇🏽 https://lnkd.in/dHCXrgcb

AstraZeneca PLC (LSE:AZN) has bought US biopharmaceutical company Icosavax, Inc.  for up to US$1.1 billion.  The Anglo-Swedish drug maker said the deal will build on its expertise in respiratory syncytial virus (RSV), and strengthen its Vaccines & Immune Therapies late-stage pipeline with Icosavax's lead investigational vaccine candidate, IVX-A12, a “potential first-in- class”.  IVX-A12 is the most advanced investigational vaccine targeting both RSV and hMPV and has a differentiated profile versus currently approved RSV vaccines, the company said.   Phase II data demonstrate that IVX-A12 elicits robust immune responses against both RSV and hMPV one month after vaccination and reconfirm previous immunogenicity data seen in the Phase I trial, the firm added.  More at #Proactive #ProactiveInvestors #LSE #AZN #Astrazeneca #Icosavax http://ow.ly/kUa01055opA

𝐆𝐒𝐊 𝐚𝐧𝐝 𝐂𝐮𝐫𝐞𝐕𝐚𝐜 𝐑𝐞𝐬𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐞 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐢𝐧𝐭𝐨 𝐍𝐞𝐰 𝐋𝐢𝐜𝐞𝐧𝐬𝐢𝐧𝐠 𝐀𝐠𝐫𝐞𝐞𝐦𝐞𝐧𝐭 GSK plc (LSE/NYSE: GSK)GSK and CureVac N.V. (Nasdaq: CVAC) CureVac announced a new licensing agreement to prioritize their respective mRNA development activities. This restructure allows GSK to take full control of developing and manufacturing mRNA vaccine candidates for seasonal influenza, COVID-19, and avian influenza, which are currently in clinical development phases. Under the new agreement, GSK will commercialize these vaccines globally, while CureVac receives an upfront payment of €400 million and up to €1.05 billion in milestones and royalties. CureVac retains rights to undisclosed infectious disease targets and can develop mRNA vaccines in other indications independently. Tony Wood, Chief Scientific Officer at GSK, stated, “We are excited about our flu/COVID-19 programs and the opportunity to develop best-in-class mRNA vaccines.” Alexander Zehnder Alexander Zehnder, MD, MBA, CEO of CureVac, added, “This new agreement strengthens our financial position and enables us to focus on building a robust R&D pipeline.” Completion of the agreement is subject to antitrust and regulatory approvals and customary closing conditions. #GSK #CureVac #mRNA #VaccineDevelopment #Biotechnology #InfectiousDiseases #PharmaPartnerships

Latest Healthcare News & Updates: Moderna Reports Successful Phase III Trials for Dual Influenza and COVID-19 Vaccine Almirall’s Klisyri Receives FDA Approval for Treating Actinic Keratosis on Expanded Facial or Scalp Areas, Now up to 100 cm² Eli Lilly and Company's Tirzepatide Outperforms Placebo in Resolving MASH, with Over 50% of Patients Showing Fibrosis Improvement within 52 Weeks Cycle Pharmaceuticals Proposes All-Cash Acquisition of Vanda Pharmaceuticals at $8.00 Per Share Ipsen’s Iqirvo Receives FDA Accelerated Approval for Treatment of Primary Biliary Cholangitis Get more detailed analysis, at: https://lnkd.in/gVPvYRBH #lifesciences #pharmaceuticals #marketresearch #marketanalysis #healthcare #markettrends #health #medical #news #healthcarenews #pharmanews #clinicaltrials #clinicalresearch